Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery

Abstract Dupilumab, a human monoclonal antibody against interleukin‐4 (IL‐4) and IL‐13, has been approved for treating severe asthma and eosinophilic chronic rhinosinusitis (ECRS). Patients with ECRS are often candidates for endoscopic sinus surgery (ESS). However, a considerable number of patients...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yoshiro Kai, Masanori Yoshikawa, Masayuki Matsuda, Atsuhiko Fukuoka, Yukio Fujita, Motoo Yamauchi, Shigeo Muro
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-08-01
coleção:	Respirology Case Reports
Assuntos:	Asthma dupilumab IL‐4 IL‐13 rhinosinusitis
Acesso em linha:	https://doi.org/10.1002/rcr2.804
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!